NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
80 trialsNCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT04102098 2026-03-19
IMbrave050
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03867084 2026-02-04
KEYNOTE-937
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04712643 2026-01-30
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07356037 2026-01-21
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06921785 2026-01-09
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT05904886 2025-12-31
SKYSCRAPER-14
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT05317819 2025-12-18
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Phase 3 Recruiting
NCT04246177 2025-12-17
LEAP-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT04194775 2025-12-11
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 3 Active not recruiting
NCT05320692 2025-12-11
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT03383458 2025-11-21
CheckMate 9DX
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT03062358 2025-09-30
MK-3475-394
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT05201404 2025-04-29
LIVERATION
Can-Fite BioPharma
Phase 3 Recruiting
NCT05489289 2025-03-12
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Akeso
Phase 3 Recruiting
NCT06371157 2025-03-12
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Akeso
Phase 3 Recruiting
NCT06841185 2025-02-24
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Shanghai Henlius Biotech
Phase 3 Not yet recruiting
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT05557838 2025-02-07
TREMENDOUS
AstraZeneca
Phase 3 Recruiting
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT05594927 2024-08-07
BESTPOP
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Recruiting
NCT00617981 2024-05-03
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon
Phase 3 Completed
NCT02329860 2024-01-22
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT00699816 2023-07-11
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
GC Cell Corporation
Phase 3 Completed
NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn
NCT05862337 2023-05-17
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT03236649 2023-02-08
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Terminated
NCT02435433 2023-01-20
REACH-2
Eli Lilly and Company
Phase 3 Completed
NCT02702401 2022-09-29
KEYNOTE-240
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01402908 2022-06-23
PATRON
Cellxpert Biotechnology Corp.
Phase 3 Terminated
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT01387932 2021-11-30
HiQuality
Merit Medical Systems, Inc.
Phase 3 Terminated
NCT01655693 2021-06-02
ReLive
Valerio Therapeutics
Phase 3 Completed
NCT01908426 2021-05-06
CELESTIAL
Exelixis
Phase 3 Completed
NCT01887717 2021-04-21
YES-P
Boston Scientific Corporation
Phase 3 Terminated
NCT01755767 2021-04-06
METIV-HCC
Daiichi Sankyo
Phase 3 Completed